133 related articles for article (PubMed ID: 38127696)
1. [Experience of clinical use of fluvoxamine for the treatment of comorbid depression in childhood and adolescence].
Goryunov AV; Golubeva NI; Shushpanova OV
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11. Vyp. 2):14-21. PubMed ID: 38127696
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
3. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Reznik I; Sirota P
J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
[TBL] [Abstract][Full Text] [Related]
4. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
[TBL] [Abstract][Full Text] [Related]
5. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
6. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
N Engl J Med; 2001 Apr; 344(17):1279-85. PubMed ID: 11323729
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer SM; Figgitt DP
CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
[TBL] [Abstract][Full Text] [Related]
10. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
12. Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Jaffe RJ; Juneja NS; Juneja NS; Jaffe RJ; Coffey BJ
J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):488-490. PubMed ID: 30226805
[No Abstract] [Full Text] [Related]
13. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
Cheer SM; Figgitt DP
Paediatr Drugs; 2001; 3(10):763-81. PubMed ID: 11706925
[TBL] [Abstract][Full Text] [Related]
14. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Mundo E; Guglielmo E; Bellodi L
Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
16. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D
J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa.
Fichter MM; Leibl C; Krüger R; Rief W
Pharmacopsychiatry; 1997 May; 30(3):85-92. PubMed ID: 9211569
[TBL] [Abstract][Full Text] [Related]
18. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.
Poyurovsky M; Isakov V; Hromnikov S; Modai I; Rauchberger B; Schneidman M; Weizman A
Int Clin Psychopharmacol; 1999 Mar; 14(2):95-100. PubMed ID: 10220124
[TBL] [Abstract][Full Text] [Related]
19. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder.
Yaryura-Tobias JA; Grunes MS; Walz J; Neziroglu F
Int Clin Psychopharmacol; 2000 May; 15(3):163-8. PubMed ID: 10870874
[TBL] [Abstract][Full Text] [Related]
20. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
Houck C
Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
